Comparative Pharmacology
Head-to-head clinical analysis: DOLISHALE versus PROPOXYPHENE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DOLISHALE versus PROPOXYPHENE HYDROCHLORIDE.
DOLISHALE vs PROPOXYPHENE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DOLISHALE is a selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the CNS by inhibiting the reuptake of serotonin at the presynaptic neuronal membrane, enhancing serotonin neurotransmission.
Propoxyphene hydrochloride is a centrally acting opioid analgesic that binds to mu-opioid receptors in the central nervous system, inhibiting ascending pain pathways and altering perception of and response to pain.
Adults: 200 mg orally twice daily or 400 mg orally once daily. Administer with food.
65 mg orally every 4 hours as needed for pain; maximum 390 mg per day.
None Documented
None Documented
Terminal elimination half-life: 12 hours (range 10-14) in adults; prolonged in renal impairment (up to 24 hours with CrCl <30 mL/min)
6–12 hours (parent drug); norpropoxyphene metabolite half-life 30–36 hours, accumulates with repeated dosing, increasing risk of toxicity, especially in elderly or renal impairment.
Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other
Primarily renal (70-90% as unchanged drug and metabolites, including norpropoxyphene); biliary/fecal excretion accounts for less than 10%.
Category C
Category C
Opioid Analgesic
Opioid Analgesic